Posts by: Alice Melao

News

Sangamo Therapeutics is preparing to launch a Phase 1/2 clinical study in the United Kingdom to explore the potential of its cell-based CAR-Treg therapy — TX200 — in preventing ... Read more

October 16, 2019October 16, 2019

Clinical Deterioration Should Not Dictate Soliris Withdrawal, Report Suggests

News

Treatment of atypical hemolytic uremic syndrome (aHUS) with Soliris (eculizumab) should be maintained even after clinical deterioration, a case report suggests. This is the first report of suboptimal response to ... Read more

July 24, 2019July 24, 2019

Study Reports Outcomes of aHUS Patients with Anti-Factor H Antibody

News

Clinical features and outcomes of patients with anti-factor H antibody, associated with atypical hemolytic uremic syndrome (aHUS), were reported in a nationwide study conducted by Indian researchers. The study, ... Read more

July 3, 2019July 3, 2019

Soliris Treatment May Trigger Antibody Accumulations in Kidneys, Case Report Suggests

News

Treatment with Soliris (eculizumab, sold by Alexion) for recurrent atypical hemolytic uremic syndrome (aHUS) can result in the accumulation of antibodies in the kidneys, a rare case suggests. The case was ... Read more

June 12, 2019June 12, 2019

Novel Mutation in CFH Gene Linked to aHUS in German Woman, Case Study Shows

News

A novel genetic variant of the CFH gene, which encodes an important protein from the immune complement system, was linked to the development of atypical hemolytic uremic syndrome (aHUS) ... Read more

March 20, 2019March 20, 2019

Toddler with aHUS-induced Seizures Highlights Importance of Early Intervention, Case Study Says

News

A rare case of atypical hemolytic uremic syndrome (aHUS) manifesting in generalized seizures in a 14-month-old girl highlights the importance of prompt diagnosis and treatment to ensure better outcomes ... Read more

March 1, 2019March 1, 2019

Potential aHUS Therapy OMS721 Receives Generic Name Narsoplimab

News

Omeros Corporation’s lead therapy candidate, OMS721, being developed for the treatment of complement- and inflammation-related disorders including atypical hemolytic uremic syndrome (aHUS), will now be known as narsoplimab, the company ... Read more

February 6, 2019February 6, 2019

Quarterly Soliris Treatment Prevented aHUS Relapse, Case Report Says

News

Interval treatment with Soliris (eculizumab) may have a steady and prolonged effect in treating people with atypical hemolytic uremic syndrome (aHUS) with limited access to the costly drug, a ... Read more

January 25, 2019January 25, 2019

Soliris Can Effectively Treat aHUS with Atypical Neurological Symptoms, Report Says

News

Treatment with Soliris (eculizumab) is an effective strategy to manage atypical hemolytic uremic syndrome (aHUS) even when manifested with atypical neurological symptoms, a rare case reported by Turkish researchers ... Read more

January 8, 2019January 9, 2019

Omeros, Cambridge Establish New Research Center Dedicated to Complement and Inflammation Disorders

News

Omeros Corporation, in collaboration with the University of Cambridge, has established a new research center that will focus on the development of therapies for complement- and inflammation-related disorders, including ... Read more